FRES - fresh2.co Long-Term Liabilities to Capital

Corporate company logo of Fresh2 Group (FRES)

The price chart for Fresh2 Group Limited (FRES) reflects the dynamics of a company operating amidst fierce competition with Asian tech giants and low brokerage margins. The business relies on the PRC agro-IT segment, where financial stability is constrained by regulatory pressure and volatile demand, with the indicator standing at 0.00. Efforts to expand its B2B platform for the food industry are being hindered by rising marketing and delivery costs.

Fresh2 (FRES): Long-Term Debt to Capital from 02/21/2024 to 01/04/2025
Core merchandise of Fresh2 Group Ltd

For Fresh2 Group Limited (FRES), which develops digital B2B logistics in the US and China, the ratio of long-term debt to equity reflects a strategy of long-term infrastructure financing. This metric compares the volume of long-term liabilities against net shareholder assets. An increase in this indicator signals a growing credit load to scale the business, while a decrease in the coefficient confirms financial stability. It is critical for investors to assess the balance between low-cost debt capital and solvency risks.

Who Fresh2 Group Limited competes with

Long-Term Debt to Equity Ratio Agilent Technologies, Inc.|Quest - Long-Term Debt to Capital|Long-Term Liabilities to Capital Illumina Platform (ILMN)|EXAS - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio revvity.com RVTY|Bio-Rad - Long-Term Debt to Capital|NNNN: Long-Term Debt to Capital|Long-Term Debt to Equity Sterigenics|QuidelOrtho Inc. (QDEL) - Long-Term Debt to Capital Ratio|OPK (OPKO Health, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital CDNA|Long-Term Debt to Equity Maravai LifeSciences Holdings, Inc. (MRVI)|Long-Term Debt to Equity Fulgent Genetics Inc FLGT|LAB: Long-Term Debt to Equity Ratio|Cytek Corp - Long-Term Liabilities to Capital|Long-Term Debt to Equity OSUR (OraSure Technologies)|XGN - Ratio of Long-Term Indebtedness to Capital|MDxHealth - Long-Term Debt to Capital|LUCD (Lucid Diagnostics, Inc.) - Ratio of Long-Term Indebtedness to Capital|PRE: Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Insight Molecular|TRIB - Long-Term Debt to Capital|Long-Term Liabilities to Equity PRPH (prophaselabs.com)|Long-Term Debt to Equity Ainos|Long-Term Debt to Capital Coefficient Co-Diagnostics Inc CODX|HSCS (Heart Test Laboratories Inc.) - Long-Term Debt to Capital|BMRA: Long-Term Liabilities to Capital|cardiodiagnosticsinc.com - Long-Term Debt to Equity|viraxbiolabs.com (VRAX) - Ratio of Long-Term Indebtedness to Capital|BJDX - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient AWH|Long-Term Debt to Equity AXDX (Accelerate Diagnostics, Inc)|CNTG (Centogene) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ENZ (Enzo Biochem)|Long-Term Debt to Capital Genetic Technologies Ltd|ME - Long-Term Indebtedness to Equity|Long-Term Debt to Equity PMD (Psychemedics Corp.)